Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)
Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnosti...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 622 - 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
01.08.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome.
Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l'Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling.
We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres.
ClinicalTrials.gov NCT04660084 . Registered on December 9, 2020. |
|---|---|
| AbstractList | BackgroundCommunity-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome.MethodsPatients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l’Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling.DiscussionWe will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres.Trial registrationClinicalTrials.govNCT04660084. Registered on December 9, 2020 Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Methods Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire[R] FilmArray[R] Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l'Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. Discussion We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. Trial registration ClinicalTrials.govNCT04660084. Registered on December 9, 2020 Keywords: Community-acquired pneumonia, Respiratory tract infections, Microbiological testing, Rapid diagnostics, FilmArray Pneumonia Panel, Syndromic PCR panel, Molecular testing, Induced sputum, Antimicrobial treatment Abstract Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Methods Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l’Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. Discussion We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. Trial registration ClinicalTrials.gov NCT04660084 . Registered on December 9, 2020 Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l'Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. ClinicalTrials.gov NCT04660084 . Registered on December 9, 2020. Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. Abstract Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Methods Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus ) (bioMérieux S.A., Marcy-l’Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. Discussion We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. Trial registration ClinicalTrials.gov NCT04660084 . Registered on December 9, 2020 Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome.BACKGROUNDCommunity-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome.Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l'Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling.METHODSPatients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l'Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling.We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres.DISCUSSIONWe will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres.ClinicalTrials.gov NCT04660084 . Registered on December 9, 2020.TRIAL REGISTRATIONClinicalTrials.gov NCT04660084 . Registered on December 9, 2020. |
| ArticleNumber | 622 |
| Audience | Academic |
| Author | Heggelund, Lars Markussen, Dagfinn Ebbesen, Marit H Kommedal, Øyvind Knoop, Siri T Ritz, Christian Bjørneklett, Rune O Faurholt-Jepsen, Daniel Serigstad, Sondre Clark, Tristan W van Werkhoven, Cornelis H Ulvestad, Elling Grewal, Harleen M S |
| Author_xml | – sequence: 1 givenname: Sondre surname: Serigstad fullname: Serigstad, Sondre organization: Department of Clinical Medicine, Faculty of Medicine, University of Bergen, Bergen, Norway – sequence: 2 givenname: Christian surname: Ritz fullname: Ritz, Christian email: ritz@sdu.dk, ritz@sdu.dk organization: National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. ritz@sdu.dk – sequence: 3 givenname: Daniel surname: Faurholt-Jepsen fullname: Faurholt-Jepsen, Daniel organization: Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark – sequence: 4 givenname: Dagfinn surname: Markussen fullname: Markussen, Dagfinn organization: Emergency Care Clinic, Haukeland University Hospital, Bergen, Norway – sequence: 5 givenname: Marit H surname: Ebbesen fullname: Ebbesen, Marit H organization: Department of Microbiology, Haukeland University Hospital, Bergen, Norway – sequence: 6 givenname: Øyvind surname: Kommedal fullname: Kommedal, Øyvind organization: Department of Microbiology, Haukeland University Hospital, Bergen, Norway – sequence: 7 givenname: Rune O surname: Bjørneklett fullname: Bjørneklett, Rune O organization: Department of Clinical Medicine, Faculty of Medicine, University of Bergen, Bergen, Norway – sequence: 8 givenname: Lars surname: Heggelund fullname: Heggelund, Lars organization: Department of Internal Medicine, Vestre Viken Hospital Trust, Drammen, Norway – sequence: 9 givenname: Tristan W surname: Clark fullname: Clark, Tristan W organization: School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK – sequence: 10 givenname: Cornelis H surname: van Werkhoven fullname: van Werkhoven, Cornelis H organization: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands – sequence: 11 givenname: Siri T surname: Knoop fullname: Knoop, Siri T organization: Department of Microbiology, Haukeland University Hospital, Bergen, Norway – sequence: 12 givenname: Elling surname: Ulvestad fullname: Ulvestad, Elling organization: Department of Microbiology, Haukeland University Hospital, Bergen, Norway – sequence: 13 givenname: Harleen M S orcidid: 0000-0002-3380-1117 surname: Grewal fullname: Grewal, Harleen M S email: harleen.grewal@uib.no, harleen.grewal@uib.no organization: Department of Microbiology, Haukeland University Hospital, Bergen, Norway. harleen.grewal@uib.no |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35915452$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUstu1DAUjVARbQd-gAWyxKZIpNjxIwkLpFHFY6SqRQjW1o0fwaPETp0ENH_Dhh_hy_DMlNJByAvb1-eee33uOc2OfPAmy54SfE5IJV6NhGJBc1wUORZMlHn5IDshJeO5KAg_unc-zk7HcY0xozVlj7JjymvCGS9Osp-rfgA1oWBRhMFp1IfOqLmDiCYzTs63KHikHbQ-jG58iaZoYOqNnxD4hAYPrdldE4MKfT97N21yUDezi0ajwZu5D94Bch5dhfgdNq8RoCFC28PkVKrqdejdmLAq-CmGrkvHKTrofv04u1h-vLr-9OJx9tBCN5ont_si-_Lu7eeLD_nl9fvVxfIyV1zQKRdEWGwFKGgohaYQFdGkKBpcCaqrEjgog63SGvOyKpqGWSCkYQnHlK450EW22vPqAGs5RNdD3MgATu4CIbYSYuq6M9LWVvGqwlpQyyqta0NrZmqMK0vNdi6L7M2ea5ib3miVNIrQHZAevnj3Vbbhm0wjwiWtEsHZLUEMN3MahkwyKdN14E2YR1mIuqSC1zVJ0Of_QNdhjj5JJYsKV1wwXLC_qBbSB5y3IdVVW1K5LJNOnGO27fv8P6i0tOldGpGxLsUPEop9gophHKOxd38kWG6NKvdGlcmocmdUWaakZ_fVuUv540z6G3KW6A0 |
| CitedBy_id | crossref_primary_10_3390_antibiotics13010067 crossref_primary_10_1016_j_accpm_2023_101300 crossref_primary_10_1097_QCO_0000000000000927 crossref_primary_10_1001_jamanetworkopen_2024_0830 crossref_primary_10_3390_antibiotics12040788 crossref_primary_10_1016_j_ijid_2024_107019 crossref_primary_10_1128_spectrum_03002_23 crossref_primary_10_3390_jcm12216864 crossref_primary_10_1016_j_eimc_2024_06_003 crossref_primary_10_1128_jcm_00505_23 |
| Cites_doi | 10.1128/JCM.00135-20 10.1056/NEJMra1312885 10.1111/crj.12283 10.1093/eurheartj/ehz486 10.2214/AJR.19.21521 10.1136/thx.2009.129502 10.1136/bmj.g3187 10.1128/JCM.00128-20 10.1038/s41598-021-03741-7 10.1016/S2213-2600(17)30120-0 10.2217/fmb.09.87 10.1001/archinte.1997.00440340089009 10.3390/vaccines6030059 10.1513/AnnalsATS.201901-007OC 10.1016/j.ijid.2010.02.2262 10.1056/NEJMoa1500245 10.1093/cid/civ1214 10.1371/journal.pone.0148741 10.1016/S1473-3099(18)30310-4 10.1136/bmj.h2147 10.1186/s12879-015-0803-5 10.1128/9781555818814 10.1016/S0140-6736(12)61901-1 10.1136/thoraxjnl-2013-204282 10.1016/j.rmed.2018.02.007 |
| ContentType | Journal Article |
| Contributor | Ravn, P Clark, T W Markussen, D Kommedal, Ø Serigstad, S Van Werkhoven, C H Bjørneklett, R Heggelund, L Ritz, C Ulvestad, E Ebbesen, M Knoop, S T Faurholt-Jepsen, D Grewal, H M S |
| Contributor_xml | – sequence: 1 givenname: R surname: Bjørneklett fullname: Bjørneklett, R – sequence: 2 givenname: T W surname: Clark fullname: Clark, T W – sequence: 3 givenname: M surname: Ebbesen fullname: Ebbesen, M – sequence: 4 givenname: D surname: Faurholt-Jepsen fullname: Faurholt-Jepsen, D – sequence: 5 givenname: H M S surname: Grewal fullname: Grewal, H M S – sequence: 6 givenname: L surname: Heggelund fullname: Heggelund, L – sequence: 7 givenname: S T surname: Knoop fullname: Knoop, S T – sequence: 8 givenname: Ø surname: Kommedal fullname: Kommedal, Ø – sequence: 9 givenname: D surname: Markussen fullname: Markussen, D – sequence: 10 givenname: P surname: Ravn fullname: Ravn, P – sequence: 11 givenname: C surname: Ritz fullname: Ritz, C – sequence: 12 givenname: S surname: Serigstad fullname: Serigstad, S – sequence: 13 givenname: E surname: Ulvestad fullname: Ulvestad, E – sequence: 14 givenname: C H surname: Van Werkhoven fullname: Van Werkhoven, C H |
| Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
| Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
| CorporateAuthor | CAPNOR study group The CAPNOR study group |
| CorporateAuthor_xml | – name: CAPNOR study group – name: The CAPNOR study group |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-022-06467-7 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_f9fc5880d63f48dd9e394e9008f3e306 A712255046 10_1186_s13063_022_06467_7 35915452 |
| Genre | Randomized Controlled Trial Pragmatic Clinical Trial Journal Article |
| GeographicLocations | Norway United Kingdom--UK Denmark |
| GeographicLocations_xml | – name: Norway – name: United Kingdom--UK – name: Denmark |
| GrantInformation_xml | – fundername: The Trond Mohn Foundation grantid: COVID-19 CAPNOR; TMS2020TMT07 and RESPNOR; BFS2019TMT06 – fundername: Research Council of Norway grantid: NORCAP; 288718 – fundername: ; – fundername: ; grantid: COVID-19 CAPNOR; TMS2020TMT07 and RESPNOR; BFS2019TMT06 – fundername: ; grantid: NORCAP; 288718 |
| GroupedDBID | --- -5E -5G -A0 -BR 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ NPM O5R O5S PGMZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX CITATION ABVAZ AFGXO AFNRJ 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO FRP K9. PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c563t-616f0f6acab33ab2681d122b0863d87a5ace0fcdd05782bb4fa11b42684cd95a3 |
| IEDL.DBID | RPM |
| ISSN | 1745-6215 |
| IngestDate | Thu Jul 04 21:12:46 EDT 2024 Tue Sep 17 21:14:23 EDT 2024 Mon Sep 02 16:43:00 EDT 2024 Fri Sep 13 03:50:14 EDT 2024 Thu Feb 22 23:34:21 EST 2024 Fri Feb 02 04:29:23 EST 2024 Thu Sep 12 19:29:21 EDT 2024 Wed Oct 02 05:27:03 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Respiratory tract infections Antimicrobial treatment Syndromic PCR panel Microbiological testing Molecular testing Community-acquired pneumonia FilmArray Pneumonia Panel Rapid diagnostics Induced sputum |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-616f0f6acab33ab2681d122b0863d87a5ace0fcdd05782bb4fa11b42684cd95a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-3380-1117 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340738/ |
| PMID | 35915452 |
| PQID | 2808564024 |
| PQPubID | 44365 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f9fc5880d63f48dd9e394e9008f3e306 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9340738 proquest_miscellaneous_2697365991 proquest_journals_2808564024 gale_infotracmisc_A712255046 gale_infotracacademiconefile_A712255046 crossref_primary_10_1186_s13063_022_06467_7 pubmed_primary_35915452 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | A Torres (6467_CR1) 2018; 137 6467_CR24 RE Isturiz (6467_CR3) 2010; 14 S Jain (6467_CR12) 2015; 373 6467_CR26 O Olasupo (6467_CR4) 2018; 6 6467_CR25 JC Holter (6467_CR14) 2016; 11 6467_CR28 6467_CR27 6467_CR29 F Cosentino (6467_CR33) 2019; 41 A Torres (6467_CR6) 2013; 68 DM Musher (6467_CR9) 2014; 371 NJ Brendish (6467_CR16) 2017; 5 S Serigstad (6467_CR19) 2022; 12 AF Gombart (6467_CR32) 2009; 4 T Welte (6467_CR11) 2012; 67 MF Olsen (6467_CR23) 2014; 348 W Roysted (6467_CR15) 2016; 10 K Loudon (6467_CR18) 2015; 350 AV Jensen (6467_CR34) 2019; 16 JP Metlay (6467_CR10) 1997; 157 6467_CR17 BW Buchan (6467_CR35) 2020; 58 H Nair (6467_CR2) 2013; 381 GBDLRI Collaborators (6467_CR5) 2018; 18 A Bjarnason (6467_CR13) 2018; 5 CN Murphy (6467_CR36) 2020; 58 6467_CR7 6467_CR8 NJ Gadsby (6467_CR21) 2016; 62 JC Holter (6467_CR22) 2015; 15 AM Leber (6467_CR20) 2016 6467_CR31 6467_CR30 |
| References_xml | – ident: 6467_CR31 – ident: 6467_CR29 – volume: 58 start-page: e00135 year: 2020 ident: 6467_CR35 publication-title: J Clin Microbiol doi: 10.1128/JCM.00135-20 contributor: fullname: BW Buchan – volume: 371 start-page: 1619 year: 2014 ident: 6467_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMra1312885 contributor: fullname: DM Musher – volume: 10 start-page: 756 year: 2016 ident: 6467_CR15 publication-title: Clin Respir J doi: 10.1111/crj.12283 contributor: fullname: W Roysted – volume: 41 start-page: 255 year: 2019 ident: 6467_CR33 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz486 contributor: fullname: F Cosentino – ident: 6467_CR8 doi: 10.2214/AJR.19.21521 – volume: 67 start-page: 71 year: 2012 ident: 6467_CR11 publication-title: Thorax doi: 10.1136/thx.2009.129502 contributor: fullname: T Welte – volume: 348 start-page: g3187 year: 2014 ident: 6467_CR23 publication-title: BMJ doi: 10.1136/bmj.g3187 contributor: fullname: MF Olsen – volume: 58 start-page: e00128 issue: 7 year: 2020 ident: 6467_CR36 publication-title: J Clin Microbiol doi: 10.1128/JCM.00128-20 contributor: fullname: CN Murphy – volume: 5 start-page: ofy010 year: 2018 ident: 6467_CR13 publication-title: Infect Dis Ther contributor: fullname: A Bjarnason – volume: 12 start-page: 326 year: 2022 ident: 6467_CR19 publication-title: Sci Rep doi: 10.1038/s41598-021-03741-7 contributor: fullname: S Serigstad – volume: 5 start-page: 401 year: 2017 ident: 6467_CR16 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(17)30120-0 contributor: fullname: NJ Brendish – volume: 4 start-page: 1151 year: 2009 ident: 6467_CR32 publication-title: Future Microbiol doi: 10.2217/fmb.09.87 contributor: fullname: AF Gombart – volume: 157 start-page: 1453 year: 1997 ident: 6467_CR10 publication-title: Arch Intern Med doi: 10.1001/archinte.1997.00440340089009 contributor: fullname: JP Metlay – volume: 6 start-page: 59 issue: 3 year: 2018 ident: 6467_CR4 publication-title: Vaccines (Basel) doi: 10.3390/vaccines6030059 contributor: fullname: O Olasupo – ident: 6467_CR28 – ident: 6467_CR26 – volume: 16 start-page: 1518 year: 2019 ident: 6467_CR34 publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201901-007OC contributor: fullname: AV Jensen – ident: 6467_CR24 – ident: 6467_CR7 – volume: 14 start-page: e852 year: 2010 ident: 6467_CR3 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2010.02.2262 contributor: fullname: RE Isturiz – volume: 373 start-page: 415 year: 2015 ident: 6467_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1500245 contributor: fullname: S Jain – volume: 62 start-page: 817 year: 2016 ident: 6467_CR21 publication-title: Clin Infect Dis doi: 10.1093/cid/civ1214 contributor: fullname: NJ Gadsby – volume: 11 start-page: e0148741 year: 2016 ident: 6467_CR14 publication-title: PLoS One doi: 10.1371/journal.pone.0148741 contributor: fullname: JC Holter – volume: 18 start-page: 1191 year: 2018 ident: 6467_CR5 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30310-4 contributor: fullname: GBDLRI Collaborators – ident: 6467_CR17 – ident: 6467_CR30 – volume: 350 start-page: h2147 year: 2015 ident: 6467_CR18 publication-title: BMJ doi: 10.1136/bmj.h2147 contributor: fullname: K Loudon – volume: 15 start-page: 64 year: 2015 ident: 6467_CR22 publication-title: BMC Infect Dis doi: 10.1186/s12879-015-0803-5 contributor: fullname: JC Holter – volume-title: Clinical microbiology procedures handbook, volume 1-3 year: 2016 ident: 6467_CR20 doi: 10.1128/9781555818814 contributor: fullname: AM Leber – volume: 381 start-page: 1380 year: 2013 ident: 6467_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(12)61901-1 contributor: fullname: H Nair – ident: 6467_CR25 – volume: 68 start-page: 1057 year: 2013 ident: 6467_CR6 publication-title: Thorax doi: 10.1136/thoraxjnl-2013-204282 contributor: fullname: A Torres – ident: 6467_CR27 – volume: 137 start-page: 6 year: 2018 ident: 6467_CR1 publication-title: Respir Med doi: 10.1016/j.rmed.2018.02.007 contributor: fullname: A Torres |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.404285 |
| Snippet | Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive... Abstract Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples... Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and... BackgroundCommunity-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and... Abstract Background Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 622 |
| SubjectTerms | Anti-Bacterial Agents - therapeutic use Anti-Infective Agents Antibiotics Antimicrobial agents Bacterial pneumonia Care and treatment Community-acquired infections Community-Acquired Infections - diagnosis Community-Acquired Infections - drug therapy Community-acquired pneumonia Diagnosis Dyspnea Emergency medical care Etiology Feasibility studies FilmArray Pneumonia Panel Hospitalization Hospitals Humans Medical diagnosis Medicine Microbiological testing Molecular Diagnostic Techniques Mortality Pathogens Patients Pneumonia Pneumonia - diagnosis Pneumonia - drug therapy Rapid diagnostics Respiratory tract infections Study Protocol Syndromic PCR panel Testing |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRkJCRBE3cSOHXNbKqqC1AUhKvVm-dmuBM5qN6uq_4YLf4Rfxth5aCMOXLhF8SSxPeN5KDPfIPSCavBStTV5hEaHAIXyXHNLcseFrZn31NhYO3y6YCdn9NN5db7T6ivmhHXwwN3GHXrhTQVCZhnxtLZWOCKoE2C6PHGkB9suqiGY6nQwWFlChxKZmh1uQFOn_5VlDiYYVAOfmKGE1v-3Tt4xStOEyR0LdHwH3e5dRzzvpryPbrhwF9087X-O30O_PqaKR9x4vFarpcU_hta3uI1YGuECNwHbLrduuXmLxyRzrAJQj4kw8Q2mKxxpr3NlYrKws3gV3BaEdqnwMuBFs75S1--wwqu1uki4r_DVYBuQG6DtM-C_w2XqC_L756uj-ZfF56-v76Oz4w_fjk7yvgtDbipGWogtmZ95pozShChdMvBwi7LUEAsRW3NVKeNm3lg7i8j4WlOvikLTiCJjrKgUeYD2QhPcI4Rr4Zg3wDblOK2UE2rmNVUFZ6o2nlQZejMwRa46sA2ZgpSayY6FElgoEwslz9D7yLeRMgJlpxsgPrIXH_kv8cnQy8h1GY8zsNaovioBJhyBseScw1ohiqNAeTChhO000-FBbmSvBjayrMGjZRCi0ww9H4fjkzG1LbhmCzRMcMIq8NMz9LATs3FJpBKpCXyG-EQAJ2uejoTlZQIJhwMA2rt-_D826Qm6VaazE_MeD9Beu966p-CLtfpZOnZ_ACagNQI priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-G3PUyIIKlp226RJ64ush8cq3Criwb6FfK4LXrrudpH7f_xDnaQfXhF8K820TTqTyUwy8xuEnlMFVqoyOg3Q6OCgUJ4qbkhqeWVK5hzVJuQOny3Y_Jx-WhbLAzTvc2FCWGWvE6OiNrUOe-STvATjgIG3QydShV0A3UzebX6moX5UOGftimlcQ9ezHMwKkGy-HFyvjJeM9ikzJZvsQHPH88s8hSUZVAUfLUsRvf9fHX1lkRoHUF5ZkU5vo1udKYlnLe_voAPr76IbZ91h-T30-2PMgMS1w1u5WRt80ZfCxU3A1vArXHts2li79e4NHoLOsfRAPQTGhDfoNpGkuUylDsHD1uCNt3v4F2uJ1x4v6u0vefkWS7zZylXEgYWvelODHAFtFxH_Ay5jnRD88mT2ZfH566v76Pz0w7eTedoVZUh1wUgDriZzU8eklooQqXIGBm-W5wpcI2JKLgup7dRpY6YBKF8p6mSWKRpAZbSpCkkeoENfe_sI4bKyzGliibScFtJWcuoUlRlnstSOFAl63fNEbFrsDRF9lpKJloMCOCgiBwVP0PvAtoEy4GbHG_V2JbppKFzldAEqyzDiaGlMZUlFbQWGkIN-TFmCXgSmizC7g4zJLkkBOhxwssSMw1jBqaNAeTyihL-px8292IhOK-zEXxlO0LOhOTwZIt28rfdAwypOWAFme4IetlI2DIkUVawJnyA-kr_RmMctfv09YoZXBDx3Uh79v1uP0c08TooQ4HiMDpvt3j4Bo6tRT-N8-gN5DC8C priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_nCeKL-G31lAiCD1rtNmnSCiKneJzC3pML9xbyuRbOdO120f1b_GedpB9c8R58K820TTozmRky8xuEXlAFXqoyOg3Q6BCgUJ4qbkhqeWVK5hzVJtQOL8_Y6Yp-PS_OD9DY7mj4gdsrQ7vQT2rVXrz5_XP_ART-fVT4kr3dwj4cTyPzFAwsKD6_hq7nlNAg8Us6nSqA7e1PmTktUga2biyiufIdM0MV8fz_3bUvma15SuUlG3VyG90anEt83EvDHXRg_V10Yzkcn99Df77EmkjcONzKTW3wj7E5Lu4C2oZf48Zj02ff1dvXeEpDx9ID9ZQqE96g-9KSbp9KHdKJrcEbb3cg1rXEtcdnTftL7t9hiTetXEdkWPiqNw1IFtAOOfIXcBk7h9xHq5PP3z6dpkN3hlQXjHQQczKXOSa1VIRIlTPwfBd5riBGIqbkspDaZk4bkwXEfKWok4uFogFdRpuqkOQBOvSNt48QLivLnCaWSAuskbaSmVNULjiTpXakSNCrkRVi04NwiBi8lEz0jBPAOBEZJ3iCPgZuTZQBQDveaNq1GPRRuMrpAvYuw4ijpTGVJRW1FXhEDuaRsQS9DLwWQfCAoVoO1Qow4QCYJY45rBWiOwqURzNK-Il6PjxKixilW-QleLoMQneaoOfTcHgypLx52-yAhlWcsAL89wQ97IVrWhIpqtgcPkF8JnazNc9HfP09goeDCsCuXj7-7_U9QTfzqBYh6fEIHXbtzj4FR6xTz6J2_QXWFzI3 priority: 102 providerName: Scholars Portal |
| Title | Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35915452 https://www.proquest.com/docview/2808564024/abstract/ https://www.proquest.com/docview/2697365991/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC9340738 https://doaj.org/article/f9fc5880d63f48dd9e394e9008f3e306 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2ISFeEPcFRmUkJECQtY0dO-GtK5u2Su2qwVDfIl9LpDWpehHav-GFP8Iv49hJqkW88dJU9Ulq59yT7xwj9JZKiFKlVqFrjQ4JCuWh5JqEhqc6YdZSpV3t8HjCzq_paBbP9lDc1MJ40L6S-XFxszgu8h8eW7lcqG6DE-tOx8OUQBpCku4-2ueENCl6ZX7BwRLaVMckrLsGI-1fVUYheF-wCm7bPRKnfnPtljPyPfv_tcx3XFMbNnnHD509Qg_rABIPqok-RnumeILuj-tX5E_R7wtf94hLi1dimWu8aDbAxRvXUaOY47LAukLY5etPeAc1x6IA6h0cxl1BVeUjm9tQKAcZNhovC7MF0c0Fzgs8KVc_xe1nLPByJea--yv8a6FLkB6grXHwN_DV7w7y59f74WA6ubz68Axdn51-G56H9V4MoYoZ2UCGyWzPMqGEJETIiEGc248iCRkR0QkXsVCmZ5XWPdcfX0pqRb8vqeslo3QaC_IcHRRlYQ4RTlLDrCKGCMNpLEwqelZS0edMJMqSOEAfG6Zky6rlRuZTlYRlFTcz4GbmuZnxAJ04vu0oXbts_0O5mme10GQ2tSoGS6UZsTTROjUkpSaF-MfCPHosQO8c1zOn1MBaJeraBJiwa4-VDTisFXI5CpRHLUq4nao93MhNVhuDdRYlENcySNRpgN7sht2ZDuBWmHILNCzlhMUQrQfoRSVmuyU10hog3hLA1prbI6A5vlV4rSkv__vMV-hB5HXHQR6P0MFmtTWvIQzbyA4o34x30L3BYPR1BMeT08n0Co7Dy-8XXzr-4QZ8jmnS8Qr6F6h0PQE |
| link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27957,27958,31754,31755,33779,33780,38551,43345,43840,43930,53827,53829,74102,74659,74769 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegk4AXxDeBAUZCAsSitbFjx7ygbtrUwVqmaZP2Zjn-KJW2pPRDaP8Pfyhnxw2LkHiL4kti587nO_vudwi9oyVYqaXRqYdGBweF8rTkhqSWC1Mw56g2Pnd4PGGjc_r1Ir-IG27LGFa50YlBUZta-z3y3awA44CBt0O_zH-mvmqUP12NJTRuoy1KwFXpoa29g8nJaXuOwAtGN6kyBdtdgsYO55ZZCksxqAjeWY4Cav-_uvnG4tQNnLyxEh0-QPejCYmHDc8folu2eoTujOMh-WP0-yhkPuLa4YWazwy-2pTAxSuPqVFNcV1h08TYzZY7uA02x6oC6jYgxr9BNwkkq-tUaR80bA2eV3YNf2Om8KzCk3rxS11_xgrPF2oa8F_hq5WpQX6ANkbCX8JlqA-CP-wPTybfTz8-QeeHB2f7ozQWY0h1zsgKXEzm-o4prUpCVJkxMHQHWVaCS0RMwVWutO07bUzfA-SXJXVqMCipB5PRRuSKPEW9qq7sc4QLYZnTxBJlOc2VFarvSqoGnKlCO5In6NOGJ3LeYG7I4KsUTDYclMBBGTgoeYL2PNtaSo-XHW7Ui6mM00864XQOqsow4mhhjLBEUCvAAHLQjz5L0HvPdOlnNXBWq5icAB32-FhyyGGs4MxRoNzuUMLf1N3mjdjIqA2W8q_sJuht2-yf9BFula3XQMMEJywHcz1Bzxopa4dEchFqwSeId-SvM-ZuSzX7EbDCBQGPnRQv_t-tN-ju6Gx8LI-PJt9eontZmCA-yHEb9VaLtX0FhteqfB1n1x-yMS-b |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bixMxFA66wuKLeHd01QiCig6dmWSSGV-krpZddesiLvQt5FoLOlN7Qfb_-EM9yaTjDoJvpTltkzn35jvnIPSUKohSldGpb40OCQrlqeKGpJbXpmLOUW187fDJlB2d0Q-zchbxT-sIq9zZxGCoTav9f-SjooLggEG2Q0cuwiJO303eLH-mfoKUv2mN4zQuoyvgJTM_zYDP-uQr5xWju6KZio3WYLvDDWaRglMGY8EHjin07__XSl9wU0MI5QWfNLmOrsVgEo877t9Al2xzE-2fxOvyW-j3caiBxK3DK7lcGPxjNwwXb3x3jWaO2wabDm23WL_CPewcywaoe2iM_wbdlZJszlOpPXzYGrxs7BaexULiRYOn7eqXPH-NJV6u5Dx0goVfbUwLkgS0ERP_HV6GSSH4-eH4dPr5y4vb6Gzy_uvhURrHMqS6ZGQDySZzmWNSS0WIVAWDkDcvCgXJETEVl6XUNnPamMy3yleKOpnnivq2MtrUpSR30F7TNvYewlVtmdPEEmk5LaWtZeYUlTlnstKOlAl6ueOJWHbdN0TIWiomOg4K4KAIHBQ8QW8923pK3zk7vNGu5iIqonC10yUYLcOIo5UxtSU1tTWEQg72kbEEPfNMF16_gbNaxjIF2LDvlCXGHM4KaR0FyoMBJTxNPVzeiY2IdmEt_kpxgp70y_6THuvW2HYLNKzmhJUQuCfobidl_ZFIWYep8AniA_kbnHm40iy-ha7hNYHcnVT3_7-tx2gf1Ep8Op5-fICuFkE_PNrxAO1tVlv7ECKwjXoUVOsPsW8yYQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+rapid+molecular+testing+on+diagnosis%2C+treatment+and+management+of+community-acquired+pneumonia+in+Norway%3A+a+pragmatic+randomised+controlled+trial&rft.jtitle=Trials&rft.au=Serigstad%2C+Sondre&rft.au=Ritz%2C+Christian&rft.au=Faurholt-Jepsen%2C+Daniel&rft.au=Markussen%2C+Dagfinn&rft.date=2022-08-01&rft.pub=BioMed+Central+Ltd&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-022-06467-7&rft.externalDocID=A712255046 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |